[Clinical Characteristics and Prognosis Analysis of Pediatric Severe Aplastic Anemia]

Yu-Li Cai1, Yang Lan1, Mei-Hui Yi1

  • 1Department of Pediatric Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.

Insights

Most children with severe aplastic anemia (SAA) achieve high survival rates with immunosuppressive therapy (IST). Recent home decoration may impact initial response but not long-term outcomes for SAA patients.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Immunology

Background:

  • Severe aplastic anemia (SAA) is a rare but serious condition in children.
  • Understanding prognostic factors is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To investigate the clinical features of pediatric SAA.
  • To identify factors influencing treatment outcomes and survival in children with SAA.

Main Methods:

  • Retrospective analysis of 205 children diagnosed with SAA between 2008 and 2018.
  • Evaluation of treatment response rates and overall survival post-immunosuppressive therapy (IST).

Main Results:

  • High response rates (CR+PR) at 3, 6, and 12 months post-IST were 50.9%, 59.0%, and 73.9%, respectively.
  • The 5-year overall survival rate was 93.1%.
  • Recent history of home/school decoration was associated with a higher early hematological response rate (P<0.05).

Conclusions:

  • Pediatric SAA patients demonstrate favorable response and survival rates with IST.
  • While recent decoration history may affect short-term hematological response, it does not impact long-term survival in SAA.
  • Birth method did not significantly influence long-term survival in multivariate analysis.
Abstract

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
556
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
18
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
19
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
20
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
27
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K